Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer

(2019) Takuro Yamamoto et al.   BREAST CANCER RESEARCH AND TREATMENT

Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials

(2019) Fausto Petrelli et al.   BREAST CANCER RESEARCH AND TREATMENT

Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer

(2019) Amy S. Clark et al.   CLINICAL CANCER RESEARCH

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

(2018) N C Turner et al.   ANNALS OF ONCOLOGY

Abstract GS6-02: The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies

(2018) MP Goetz et al.   CANCER RESEARCH

Abstract P2-09-10: Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study

(2018) RS Finn et al.   CANCER RESEARCH

Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

(2018) HS Rugo et al.   CANCER RESEARCH

Abstract PD5-01: Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)

(2018) M Martin et al.   CANCER RESEARCH

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

(2018) Luca Gianni et al.   LANCET ONCOLOGY

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

(2018) Debu Tripathy et al.   LANCET ONCOLOGY

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

(2018) Neil O'Brien et al.   MOLECULAR CANCER THERAPEUTICS

Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial

(2018) Nicholas C. Turner et al.   CANCER RESEARCH

Expression of MT4-MMP, EGFR and RB in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy

(2018) Pierre Foidart et al.   CLINICAL CANCER RESEARCH

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1

(2017) Tongzheng Liu et al.   Nature Communications

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells

(2017) Chun-Yu Liu et al.   PLoS One

Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)

(2016) R. Finn et al.   ANNALS OF ONCOLOGY

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

(2016) Shom Goel et al.   CANCER CELL

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer

(2016) Yutaka Fujiwara et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

(2016) J. R. Infante et al.   CLINICAL CANCER RESEARCH

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases

(2016) Per Hydbring et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer

(2015) S. E. Wardell et al.   CLINICAL CANCER RESEARCH

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

(2014) Sadhna R. Vora et al.   CANCER CELL

CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment

(2014) A. DeMichele et al.   CLINICAL CANCER RESEARCH

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer.

(2014) S. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Cyclin D activates the Rb tumor suppressor by mono-phosphorylation

(2014) Anil M Narasimha et al.   eLife

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

(2012) L. Malorni et al.   BREAST CANCER RESEARCH AND TREATMENT

The Requirement for Cyclin D Function in Tumor Maintenance

(2012) Yoon Jong Choi et al.   CANCER CELL

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

(2012) Jeffry L. Dean et al.   CELL CYCLE

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

CDK Inhibitors: Cell Cycle Regulators and Beyond

(2008) Arnaud Besson et al.   DEVELOPMENTAL CELL